<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04387630</url>
  </required_header>
  <id_info>
    <org_study_id>R.20.05.834</org_study_id>
    <nct_id>NCT04387630</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Chemotherapy With or Without Metformin in Early Breast Cancer.</brief_title>
  <official_title>Neoadjuvant Chemotherapy With or Without Metformin in Early Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Metformin is a widely used anti-diabetic drug. Several studies have pointed out a potentially
      beneficial effect of metformin therapy in diabetic cancer patients. Several studies are
      investigating the anti-tumor effect of metformin in early breast cancer. However, the
      enhancing effect of metformin on anti-tumor immunity has only been demonstrated in animal
      models. This study examines the immune effect of metformin in breast cancer patients treated
      with preoperative chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 5, 2020</start_date>
  <completion_date type="Anticipated">May 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 5, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Response rate</measure>
    <time_frame>at three months from starting therapy.</time_frame>
    <description>Response to preoperative therapy as per ultrasonographic tumor size assessment. A responder will have &gt; 50% decrease in the size of the primary tumor without appearance of new lesions.</description>
  </primary_outcome>
  <other_outcome>
    <measure>T-cell cytotoxic markers.</measure>
    <time_frame>procedure</time_frame>
    <description>Percentage of cells staining positive per high power field for the T-cell cytotoxic markers (Granzyme-B, Perforin &amp; CD-8) using immunohistochemistry (IHC).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>metformin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>metformin 850 mg once daily increased within 3 weeks to a maximum dose of 2550 mg on three divided daily doses.
Neoadjuvant cytotoxic chemotherapy as per MDT (multi-disciplinary team) decision. Patients scheduled for AC-T (adriamycin, Cyclophosphamide, paclitaxel) or AC (adriamycin, cyclophosphamide) will be eligible to randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo. Neoadjuvant cytotoxic chemotherapy as per MDT(multi-disciplinary team) decision. Patients scheduled for AC-T (adriamycin, Cyclophosphamide, paclitaxel) or AC (adriamycin, cyclophosphamide) will be eligible to randomization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Oral hypoglycemic drug. Initial dose 500-850 mg/d. incrementally increased to a maximum daily dose of 2550 mg in three divided doses.</description>
    <arm_group_label>metformin group</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Simethicone 60 mg three times daily.</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven breast carcinoma.

          -  American Society of Anesthesiology (ASA) score I-II.

          -  Candidate for neoadjuvant chemotherapy as per hospital's protocol.

          -  Clinically measurable tumor.

          -  No evidence of distant metastasis.

          -  Normal renal and liver functions.

          -  Non-diabetics.

        Exclusion Criteria:

          -  Pregnant or lactating women.

          -  Metastatic breast cancer patients.

          -  Patients with hepatic impairment.

          -  Patients with renal impairment.

          -  Diabetics.

          -  Patients unwilling to participate or withdrawing from the trial.

          -  Psychological/ mental impairment.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osama Hussein, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mansoura University Faculty of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Osama Hussein</last_name>
    <phone>0020 1099 8151 10</phone>
    <email>osama.hussein@mail.mcgill.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mansoura University Cancer center</name>
      <address>
        <city>Mansoura</city>
        <zip>35516</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Osama Hussein</last_name>
      <phone>00201099815110</phone>
      <email>osama.hussein@mail.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Saleh Elbalka</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adel Denewer</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mosab Shetewy</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sameh Roshdy</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zyad Emara</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Eikawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E, Udono H. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1809-14. doi: 10.1073/pnas.1417636112. Epub 2015 Jan 26.</citation>
    <PMID>25624476</PMID>
  </reference>
  <reference>
    <citation>Pearce EL, Walsh MC, Cejas PJ, Harms GM, Shen H, Wang LS, Jones RG, Choi Y. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature. 2009 Jul 2;460(7251):103-7. doi: 10.1038/nature08097. Epub 2009 Jun 3.</citation>
    <PMID>19494812</PMID>
  </reference>
  <reference>
    <citation>Coyle C, Cafferty FH, Vale C, Langley RE. Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Ann Oncol. 2016 Dec;27(12):2184-2195. doi: 10.1093/annonc/mdw410. Epub 2016 Sep 28. Review.</citation>
    <PMID>27681864</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 11, 2020</study_first_submitted>
  <study_first_submitted_qc>May 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2020</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Osama Hussein</investigator_full_name>
    <investigator_title>Professor of Surgery</investigator_title>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>metformin</keyword>
  <keyword>anti-tumor immunity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

